colon cancer – Medxy AI

Defining Cure in Stage II-III Colon Cancer: Insights from a Pooled Analysis of 15 Randomized Trials

By MedXY 10/04/2025

A rigorous pooled analysis of over 35,000 patients identifies a recurrence risk below 0.5% at 6 years post-surgery, providing a practical benchmark for defining cure in stage II-III colon cancer and refining patient management strategies.

Clinical Updates Oncology

Adjuvant Aspirin in PIK3CA-Mutated Colon Cancer: Insights from the SAKK 41/13 Randomized Trial

By MedXY 09/19/2025

The SAKK 41/13 trial provides the first prospective randomized evidence that adjuvant aspirin may improve disease-free survival in patients with resected PIK3CA-mutated stage II and III colon cancer, suggesting its potential as a safe, cost-effective adjuvant strategy.

Family Medicine & Nutrition news Oncology Specialties

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer: Impact on Survival Outcomes

By MedXY 08/19/2025

A 3-year structured exercise program post-adjuvant chemotherapy significantly improves disease-free and overall survival in colon cancer patients, based on the CHALLENGE phase 3 RCT involving 889 patients.

Clinical Updates news Oncology Specialties

Personalizing Oxaliplatin Dosing: Reducing Neurotoxicity in Stage III Colon Cancer—Insights from the LEANOX Trial

By MedXY 08/07/2025

LBM-based oxaliplatin dosing significantly reduces peripheral neurotoxicity without compromising survival outcomes in adjuvant treatment for stage III colon cancer.